Version May 2024
| International Prognostic Index[1] | |||
| Age >60 | |||
| Serum lactate dehydrogenase concentration above normal | |||
| ECOG performance status ≥2 | |||
| Ann Arbor stage III or IV | |||
| Number of extranodal disease sites >1 | |||
| One point is given for each of the above characteristics present in the patient, for a total score ranging from 0 to 5. When applied to the initial group of 2031 patients with aggressive NHL treated with anthracycline-based regimens that did not include rituximab, 5-year OS and CR rates according to score were as follows: | |||
| Score | Risk group | 5-year OS (%) | CR rate (%) |
| 0 to 1 | Low risk | 73 | 87 |
| 2 | Low-intermediate risk | 51 | 67 |
| 3 | High-intermediate risk | 43 | 55 |
| 4 to 5 | High risk | 26 | 44 |
| This same score applied to 1063 patients with CD20-positive aggressive lymphoma treated with rituximab plus CHOP or CHOP-like chemotherapy predicted the following[2]: | |||
| Score | 3-year EFS | 3-year PFS | 3-year OS |
| 0 to 1 | 81 | 87 | 91 |
| 2 | 69 | 75 | 81 |
| 3 | 53 | 59 | 65 |
| 4 to 5 | 50 | 50 | 59 |
| Age-adjusted International Prognostic Index[1] | |||
| For this score, all of the prognostic factors listed above, with the exception of age and number of extranodal sites, are given 1 point, for a score ranging from 0 to 3. When applied to the group of 761 patients >60 years of age, 5-year OS and CR rates according to the adjusted score were as follows: | |||
| Score | Risk group | 5-year OS (%) | CR rate (%) |
| 0 | Low risk | 56 | 91 |
| 1 | Low-intermediate risk | 44 | 71 |
| 2 | High-intermediate risk | 37 | 56 |
| 3 | High risk | 21 | 36 |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
